N
BSPM

Natixis’s Biostar Pharmaceuticals, Inc. BSPM Stock Holding History

Natixis’s Portfolio BSPM Stock Details BSPM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-3,829
Closed -$54K – 565
2014
Q1 		$54K Buy
3,829
+2,115
+123% +$33.5K ﹤0.01% 489
2013
Q4 		$24K Buy
+1,714
New +$18.5K ﹤0.01% 560

Other funds holding BSPM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
EGA
Eagle Global Advisors Houston, Texas $2.78B AUM 26.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
AL
Airain Ltd St. Peter Port, Guernsey $2.26B AUM 12.43% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Natixis's BSPM Position: Q2 2014 in Review

Natixis sold out of Biostar Pharmaceuticals, Inc. (BSPM) in Q2 2014, closing a stake of 3,829 shares — an estimated $54K sold.

Natixis first reported a position in BSPM in Q4 2013 and held it in 2 quarters. The position peaked at $54K in Q1 2014. 13 funds tracked by Wall St. Rank hold BSPM as of Q2 2014.

  • Natixis reported no remaining Biostar Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • Natixis sold 3,829 Biostar Pharmaceuticals, Inc. shares in Q2 2014, an estimated $54K.
  • Natixis first reported a position in Biostar Pharmaceuticals, Inc. in Q4 2013 and held it in 2 quarters.
  • Natixis's Biostar Pharmaceuticals, Inc. position peaked at $54K in Q1 2014.
  • 13 funds tracked by Wall St. Rank held Biostar Pharmaceuticals, Inc. as of Q2 2014.

Based on Natixis's 13F filing for Q2 2014, filed 14 Aug 2014.